Physician profile
Samir R Shaikh
NPI 1811159593
$2,923.23
in general payments reported to CMS, 2019-2025
15 companies · $347 in 2025
The $347 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $358 · 2020: $525 · 2021: $599 · 2022: $487 · 2023: $312 · 2024: $294 · 2025: $347.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $953.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $953.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $1,408.31 | 2019-2024 | Xarelto |
| Abbvie INC. | $358.17 | 2023-2025 | Dalvance, Teflaro |
| Pfizer INC. | $256.53 | 2019-2024 | |
| E.R. Squibb & Sons, L.L.C. | $181.16 | 2019-2024 | Eliquis, Camzyos |
| Novo Nordisk INC | $113.27 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $103.28 | 2020 | |
| Neurocrine Biosciences, INC. | $102.67 | 2025 | |
| Philips North America LLC | $78.82 | 2019-2024 | (Ak6) Vest Therapy |
| Shionogi INC | $73.86 | 2021 | |
| Allergan, INC. | $73.15 | 2019-2020 | |
| Procept Biorobotics Corporation | $70.22 | 2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $30.66 | 2024 | Xifaxan, Trulance |
| Bioxcel Therapeutics, INC. | $27.72 | 2024 | Igalmi |
| Portola Pharmaceuticals, LLC | $24.53 | 2020 | |
| Alexion Pharmaceuticals, INC. | $20.88 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Samir Shaikh listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.